Tramadol Risks: Study Finds More Harm Than Benefits

A recent study has raised concerns about tramadol, a commonly prescribed painkiller, suggesting that its risks may outweigh its benefits for many patients. The findings prompt renewed scrutiny of the drug’s safety profile and usage guidelines.

Tramadol Under Scrutiny: New Data Challenge Its Role

Once considered a go-to option for managing persistent pain, tramadol is facing renewed criticism as fresh research calls its benefits into question. For years, the drug was perceived as a “milder” alternative to other opioids. Yet, recent findings published in the respected journal BMJ Journals are prompting both prescribers and patients to reassess its true value—especially as prescriptions continue to climb globally, with the United States seeing particularly sharp increases.

A Closer Look at Efficacy

In what may be one of the most comprehensive reviews to date, researchers led by Professor Jehad Ahmad Barakji at the Copenhagen Trial Unit evaluated 19 clinical trials involving over 6,500 adults. Participants suffered from conditions like osteoarthritis, neuropathic pain, lower back pain, or fibromyalgia. The team sought to measure how much tramadol actually reduced pain compared to a placebo. The outcome? On a widely used scale from 0 to 10, patients saw their pain decrease by less than one point (precisely 0.93). For most specialists in chronic pain, such a modest improvement falls short of being noticeable in daily life.

The Weight of Side Effects

More concerning still are the associated risks. Data indicate that patients taking tramadol are nearly twice as likely to experience serious adverse effects compared to those on a placebo (odds ratio: 2.13). Cardiac issues—including chest pain, coronary disease, and heart failure—are especially common. Some studies have even hinted at a potential connection between tramadol use and certain cancers; however, experts caution that more evidence is needed before drawing firm conclusions. Daily inconveniences reported by patients include:

• Nausea
• Dizziness
• Constipation
• Drowsiness

Worryingly, no significant improvements in quality of life were observed among users—and data on dependence or depression remain limited.

Time for Alternatives?

With opioids linked to roughly 600,000 deaths annually worldwide—more than 80,000 in the U.S. alone in 2022—the medical community faces growing pressure to rethink its approach. Many now advocate prioritizing non-opioid solutions such as physical therapy, paracetamol, or other safer medications when treating chronic pain. This renewed debate signals a pivotal moment for millions seeking relief that doesn’t compromise their overall health.